424 related articles for article (PubMed ID: 30937639)
1. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
4. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
5. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
6. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
[TBL] [Abstract][Full Text] [Related]
7. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Treatment of Metastatic Renal Cell Carcinoma.
Bergerot P; Burns K; Prajapati D; Fox R; Salgia M; Pal SK
Cancer Treat Res; 2018; 175():127-137. PubMed ID: 30168120
[TBL] [Abstract][Full Text] [Related]
11. [Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO; Leucht K; Foller S; Grünwald V
Urologe A; 2020 Feb; 59(2):155-161. PubMed ID: 32006060
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
[TBL] [Abstract][Full Text] [Related]
13. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
Schmidinger M
Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
[TBL] [Abstract][Full Text] [Related]
14. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
Atkins MB; Tannir NM
Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
[TBL] [Abstract][Full Text] [Related]
16. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Rini BI; Battle D; Figlin RA; George DJ; Hammers H; Hutson T; Jonasch E; Joseph RW; McDermott DF; Motzer RJ; Pal SK; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
J Immunother Cancer; 2019 Dec; 7(1):354. PubMed ID: 31856918
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibition for the treatment of renal cell carcinoma.
Stühler V; Maas JM; Rausch S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2020 Jan; 20(1):83-94. PubMed ID: 31587590
[No Abstract] [Full Text] [Related]
19. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Perego G; Barzaghi P; Vavassori I; Petrelli F
Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
[TBL] [Abstract][Full Text] [Related]
20. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK
Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
